Buy Crypto Markets Spot FuturesGOLD Earn Event Center

PANews reported on March 18 that Xbow, a startup building AI software to detect application security vulnerabilities, has completed a new funding round, valuingPANews reported on March 18 that Xbow, a startup building AI software to detect application security vulnerabilities, has completed a new funding round, valuing

AI security startup Xbow surpasses $1 billion valuation

Author: PANews

Source: PANews

2026/03/18 19:38

1 min read

1$0.0002964-11.62%

For feedback or concerns regarding this content, please contact us at [email protected]

PANews reported on March 18 that Xbow, a startup building AI software to detect application security vulnerabilities, has completed a new funding round, valuing the company at over $1 billion, demonstrating investor enthusiasm for using AI in cybersecurity. Xbow announced on Wednesday that DFG Growth and Northzone led the $120 million funding round. Other participants included Alkeon Capital and Sofina, as well as existing investors Sequoia Capital, Altimeter Capital, and NFDG. The startup currently has approximately 150 employees and expects to reach several hundred by the end of the year. Xbow CEO De Mohr stated that Xbow already has over 100 clients, including Moderna and Samsung Electronics, and is seeing strong demand in South Korea.

Market Opportunity

Ucan fix life in1day Price(1)

$0.0002964

$0.0002964$0.0002964

-0.73%

USD

Ucan fix life in1day (1) Live Price Chart

Disclaimer: The articles reposted on this site are sourced from public platforms and are provided for informational purposes only. They do not necessarily reflect the views of MEXC. All rights remain with the original authors. If you believe any content infringes on third-party rights, please contact [email protected] for removal. MEXC makes no guarantees regarding the accuracy, completeness, or timeliness of the content and is not responsible for any actions taken based on the information provided. The content does not constitute financial, legal, or other professional advice, nor should it be considered a recommendation or endorsement by MEXC.